Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D.; Bartlett, N.; Burke, J. M.; Lynch, R. C.; Domingo‐Domenech, E.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Analysis of real‐world treatment patterns and outcomes among patients with relapsed/refractory follicular lymphoma including POD24 patients
    Meeting Abstract

    Sehn, L. H.; Wang, A.; Yu, J.; Kamalakar, R.; Sail, K.; Sinai, W.; Arnette, D.; Yang, S.; Mutebi, A.; Navarro, F. R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genomic correlates of radiosensitivity in diffuse large B cell lymphoma
    Meeting Abstract

    Sarkar, R. R.; Ma, J.; Wijetunga, N. A.; Salles, G.; Joffe, E.; Imber, B.; Yahalom, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0
    Meeting Abstract

    Manni, M.; Chiattone, C. S.; Prince, M. H.; Pavlovsky, A.; Tomuleasa, C.; Miranda, E.; Kriachok, I.; Hawkes, E. A.; Fiad, L.; Hitz, F.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies
    Meeting Abstract

    Serganova, I.; Bucktrout, R.; Isshiki, Y.; Sarapulov, A.; Santella, A.; Rodriguez, M.; Chakraborty, S.; Brunschvig, S.; Qualls, D.; Vardhana, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response
    Meeting Abstract

    Nastoupil, L. J.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López‐Guillermo, A.; Martínez‐López, J.; Novak, U.; Ribrag, V.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the phase 2 redirect study
    Meeting Abstract

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhaylova, N.; Marin‐Niebla, A.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save